AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
Log in

OTCMKTS:NVLNFNovelion Therapeutics Stock Price, Forecast & News

$0.70
0.00 (0.00 %)
(As of 01/16/2020)
Add
Compare
Today's Range
$0.70
Now: $0.70
$0.75
50-Day Range
$0.70
MA: $0.70
$0.70
52-Week Range
$0.51
Now: $0.70
$1.00
Volume26,947 shs
Average Volume261,364 shs
Market Capitalization$13.77 million
P/E RatioN/A
Dividend YieldN/A
Beta2.15
Novelion Therapeutics Inc., a biopharmaceutical company, develops therapies for individuals living with rare diseases in the United States, Japan, Brazil, and internationally. Its commercial products include metreleptin, a recombinant analog of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPTA brand name; and lomitapide capsule for the treatment of adult patients with homozygous familial hypercholesterolemia under the JUXTAPID and LOJUXTA brands. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.66 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:NVLNF
CUSIPN/A
CIKN/A
Phone617-500-7867

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$130.43 million
Book Value($4.69) per share

Profitability

Miscellaneous

Employees109
Market Cap$13.77 million
Next Earnings DateN/A
OptionableOptionable

Receive NVLNF News and Ratings via Email

Sign-up to receive the latest news and ratings for NVLNF and its competitors with MarketBeat's FREE daily newsletter.

Novelion Therapeutics (OTCMKTS:NVLNF) Frequently Asked Questions

How has Novelion Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Novelion Therapeutics' stock was trading at $0.7020 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NVLNF stock has increased by 0.0% and is now trading at $0.7020. View which stocks have been most impacted by Coronavirus.

Has Novelion Therapeutics been receiving favorable news coverage?

News articles about NVLNF stock have trended extremely negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Novelion Therapeutics earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutNovelion Therapeutics.

Who are some of Novelion Therapeutics' key competitors?

Who are Novelion Therapeutics' key executives?

Novelion Therapeutics' management team includes the following people:
  • Mr. Benjamin S. Harshbarger, Interim CEO, Gen. Counsel & Corp. Sec. (Age 50)
  • Mr. Michael D. Price, Exec. VP, CFO & Director (Age 61)
  • Ms. Barbara Y. Chan, VP & Chief Accounting Officer (Age 55)
  • Ms. Amanda Murphy, Director of Investor Relations & Corp. Communications
  • Ms. Linda Buono, Sr. VP of HR (Age 53)

What is Novelion Therapeutics' stock symbol?

Novelion Therapeutics trades on the OTCMKTS under the ticker symbol "NVLNF."

How do I buy shares of Novelion Therapeutics?

Shares of NVLNF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novelion Therapeutics' stock price today?

One share of NVLNF stock can currently be purchased for approximately $0.70.

How big of a company is Novelion Therapeutics?

Novelion Therapeutics has a market capitalization of $13.77 million and generates $130.43 million in revenue each year. Novelion Therapeutics employs 109 workers across the globe.

What is Novelion Therapeutics' official website?

The official website for Novelion Therapeutics is www.novelion.com.

How can I contact Novelion Therapeutics?

Novelion Therapeutics' mailing address is 1800 - 510 WEST GEORGIA STREET, VANCOUVER A1, V6B 0M3. The company can be reached via phone at 617-500-7867 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.